Key result
Various interventions, including LCZ696, iron deficiency treatment, ivabradine, beta-blockers, and vagal stimulation, were reviewed in the context of recent cardiology trials presented at ESC 2014.
This review summarizes major clinical trials presented at ESC 2014, highlighting significant updates in heart failure and atrial fibrillation management.
Summarizes 2014 ESC HF/AF trial updates; leaves open need for contemporary evidence synthesis.
This article provides an overview of trials relevant to the pathophysiology, prevention, and treatment of heart failure, presented at the European Society of Cardiology meeting held in Barcelona in autumn 2014. Trials reported here include PARADIGM-HF (LCZ696 versus enalapril in heart failure), CONFIRM-HF (treatment of iron deficiency in heart failure), and SIGNIFY (ivabradine in patients with stable coronary artery disease). In addition, we discuss recent developments in the treatment of atrial fibrillation and the lack of benefit with the use of beta-blockers in these patients. Finally, the article describes recent advances in the use of vagal stimulation in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Clark et al. (2014) conducted a review in Heart failure, stable coronary artery disease, atrial fibrillation. Various interventions (LCZ696, iron deficiency treatment, ivabradine, beta-blockers, vagal stimulation) was evaluated. Various interventions, including LCZ696, iron deficiency treatment, ivabradine, beta-blockers, and vagal stimulation, were reviewed in the context of recent cardiology trials presented at ESC 2014.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: